No Data
A soft trend with selling first, but a solid performance at lower prices may occur.
[Emerging Markets Individual Stock Strategy] The Emerging Markets are expected to have a weak performance today. In yesterday's U.S. stock market on the 2nd, the Dow Inc gained 235.36 dollars (+0.56%) to close at 42,225.32 dollars. Selling pressure continued as concerns over the Trump administration's announcement of reciprocal tariffs weighed on stock prices. On the other hand, the private sector ADP Employment Statistics reported growth that exceeded Financial Estimates, leading to increased buying as fears of an economic downturn eased. Additionally, the highest tariff rates were announced, with plans to lower them depending on subsequent negotiations.
Medurek, DWTI and others [Emerging Markets press release]
<4496> Commerce One has completed its acquisition of its own stocks. <4575> The period for the collaborative research agreement with the Pharma Valley project concerning CANVAS DO/TDO inhibitors has been extended. <4576> The approval application for DWTI's nerve pain treatment drug "DW-5LBT" has been accepted in the USA. <4586> Medreck MRX-5LBT: The approval application has been accepted by the USA FDA. <4884> Additional analysis of the Phase II clinical trial targeting ALS (physician-led clinical trial): Extended collaborative research with Tohoku University.
Kringle Pharma Releases Updated Analyst Report to Enhance Investor Insight
Kringle Pharma Reports Flat Sales and Continued Losses
With a soft tone, profit-taking Sell is likely to dominate due to the decline in U.S. stocks and the rise in U.S. long-term Gold interest rates.
[Emerging Markets Individual Stock Strategy] Today's Emerging Markets are expected to experience a sluggish trend. Last weekend, on the 7th, the Dow Inc. dropped by 444.23 dollars (-0.99%) to 44,303.40 dollars, continuing its decline. In addition, the unexpected acceleration in wage growth from the employment statistics and the rise in expected inflation rates from the University of Michigan's Consumer Sentiment Index raised concerns about a resurgence of inflation. Furthermore, President Trump stated that he would announce mutual tariff plans next week, which accelerated selling due to concerns about worsening trade friction. Today’s
Kringle Pharma: Responses to questions received in preparation for the announcement of financial results for the first quarter of the fiscal year ending September 2025